REGN Regeneron PharmaceuticalscompanySEC Filings & Insider Trading Activity 2026
Latest Regeneron Pharmaceuticals (REGN) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 4, 2026, a 10-Q quarterly report filed on October 28, 2025, an 8-K current report filed on April 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Regeneron Pharmaceuticals (REGN) (SEC CIK 872589), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Risk Factors
- • Lease financing $720M matures March 2027, full payment due unless extended with lender consent
- • Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio
Management Discussion & Analysis
- • No revenue or profitability figures provided in the excerpt
- • No segment performance details disclosed
Business Overview
- • Core business model: Development, manufacturing, and commercialization of innovative biologic drugs and drug-delivery devices with regulatory approval focus
- • New emphasis on expanding internal manufacturing capacity and establishing fill/finish capabilities amid production constraints and pandemic-related impacts
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: FDA Complete Response Letters (CRLs) for odronextamab BLA and EYLEA HD pre-filled syringe delayed approvals in 2025 due to manufacturing inspection issues
- • Most updated risk: Biosimilar competition intensifying post-EYLEA US exclusivity expiration May 2024, causing 39-41% decline in US EYLEA sales in 2025
Management Discussion & Analysis
- • Revenue $3.75B in Q3 FY2025, up slightly by $33.6M from $3.72B in Q3 FY2024
- • Net income $1.46B in Q3 FY2025 vs $1.34B Q3 FY2024; operating margin 27.3% vs 31.7% YoY (operating income $1.03B vs $1.18B)
Annual Reports Archive10-K
AI-powered analysis of Regeneron Pharmaceuticals (REGN) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Regeneron Pharmaceuticals (REGN) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $12.2B | $13.1B | $14.2B | $14.3B |
| Operating Income | $4.7B | $4.0B | $4.0B | $3.6B |
| Net Income | $4.3B | $4.0B | $4.4B | $4.5B |
| Op. Margin | 38.9% | 30.9% | 28.1% | 24.9% |
| Net Margin | 35.6% | 30.1% | 31.1% | 31.4% |
| Balance Sheet | ||||
| Total Assets | $29.2B | $33.1B | $37.8B | $40.6B |
| Equity | $22.7B | $26.0B | $29.4B | $31.3B |
| ROE | 19.1% | 15.2% | 15.0% | 14.4% |
Source: XBRL financial data from Regeneron Pharmaceuticals (REGN) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 29, 2026 | — | — | — |
8-K | Apr 8, 2026 | — | — | — |
10-K | Feb 4, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 30, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Oct 28, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 1, 2025 | Jun 30, 2025 | Analysis | |
10-Q | Apr 29, 2025 | Mar 31, 2025 | Analysis | |
10-K | Feb 5, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Feb 5, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 6, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 7, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 8, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest REGN SEC filings in 2026?
Regeneron Pharmaceuticals (REGN) has filed a 10-K annual report on February 4, 2026, a 10-Q quarterly report on October 28, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did REGN file its most recent 10-K annual report?
Regeneron Pharmaceuticals (REGN) filed its most recent 10-K annual report on February 4, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view REGN 10-Q quarterly reports?
Regeneron Pharmaceuticals (REGN)'s most recent 10-Q quarterly report was filed on October 28, 2025. SignalX displays every REGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has REGN filed recently?
Regeneron Pharmaceuticals (REGN)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find REGN insider trading activity (Form 4)?
SignalX aggregates every REGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does REGN file with the SEC?
Regeneron Pharmaceuticals (REGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new REGN filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Regeneron Pharmaceuticals (REGN).
What is REGN's SEC CIK number?
Regeneron Pharmaceuticals (REGN)'s SEC CIK (Central Index Key) number is 872589. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 872589 to look up all REGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find REGN return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Regeneron Pharmaceuticals (REGN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Regeneron Pharmaceuticals SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 41+ filings.